The United States Court of Appeals for the Eighth Circuit has affirmed a lower court’s decision to maintain a preliminary injunction against a Minnesota statute intended to curb excessive price increases on generic and biosimilar drugs. This law, targeting pharmaceutical manufacturers that impose “excessive” price hikes, was deemed likely unconstitutional on the basis of its potential to regulate prices beyond the state’s borders. This ruling underscores ongoing judicial deliberations concerning state-level efforts to control drug pricing, reflecting broader national debates on the balance between state authority and interstate commerce.
For further detailed coverage, you can read the full article at Law360.